Home Metabolism Mitochondrial pyruvate carrier inhibitor Azemiglitazone (MSDC-0602)

research use only

Azemiglitazone (MSDC-0602) Mitochondrial pyruvate carrier inhibitor

Cat.No.S7454

Azemiglitazone (MSDC-0602) is a direct mitochondrial pyruvate carrier (MPC) inhibitor that modulates central carbon metabolism in mice and humans.

Azemiglitazone (MSDC-0602) Mitochondrial pyruvate carrier inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 371.41

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S745401 DMSO]82 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.52%
99.52

Chemical Information, Storage & Stability

Molecular Weight 371.41 Formula

C19H17NO5S

 Storage (From the date of receipt) 3 years-21°C powder
CAS No. 1133819-87-0 -- Storage of Stock Solutions

Synonyms N/A Smiles COC1=CC=CC(=C1)C(=O)COC2=CC=C(CC3SC(=O)NC3=O)C=C2

Solubility

In vitro
Batch:

DMSO : 82 mg/mL (220.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
MPC [1]
In vitro

Azemiglitazone (MSDC-0602) is a modified hiazolidinediones (TZDP) with alterations in the carbon backbone that limit the ability to bind PPARγ, with the IC50 for PPARγ of 18.25 μM. This compound also shows the affinity for mitochondrial binding, with the IC50 of 1.38 μM. Using a Gal4-PPARγ construct containing the ligand binding domain of mouse PPARγ, this chemical only minimally activates Gal4-PPARγ in HepG2 cells even at a concentration of 50 μM.[1][2]
Kinase Assay
PPAR Binding Assays
TZD binding to the ligand binding domain of PPARγ was assessed in a LanthaScreen TMTR-FRET competitive binding assay performed according the protocol of the manufacturer (Invitrogen). IC 50 values for the PPARγ LanthaScreen were determined using Gen5 software (BioTek Instruments, Inc.). R2 values for individual IC50 values ranged from 0.983 to 0.999 based on three separate assays for this compound.
In vivo

Azemiglitazone (MSDC-0602) corrects plasma glucose, nonesterified fatty acids, triglycerides, cholesterol, and insulin concentrations, which are elevated in ob/ob mice compared with lean controls. Treatment with this compound also significantly improved glucose and insulin tolerance in ob/ob mice.[2]
References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.